Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
mTOR regulates T cell exhaustion and PD-1–targeted immunotherapy response during chronic viral infection
Satomi Ando, … , Rafi Ahmed, Koichi Araki
Satomi Ando, … , Rafi Ahmed, Koichi Araki
Published November 15, 2022
Citation Information: J Clin Invest. 2023;133(2):e160025. https://doi.org/10.1172/JCI160025.
View: Text | PDF
Research Article Immunology Infectious disease

mTOR regulates T cell exhaustion and PD-1–targeted immunotherapy response during chronic viral infection

  • Text
  • PDF
Abstract

T cell exhaustion is a state of T cell dysfunction associated with expression of programmed death 1 (PD-1). Exhausted CD8+ T cells are maintained by self-renewing stem-like T cells that provide differentiated TIM3+ cells, a part of which possesses effector-like properties. PD-1–targeted therapies enhance T cell response by promoting differentiation of stem-like T cells toward TIM3+ cells, but the role of mTOR during T cell exhaustion remains elusive. Here, we showed that mTOR inhibition has distinct outcomes during the beginning of and after the establishment of chronic viral infection. Blocking mTOR during the T cell expansion phase enhanced the T cell response by causing accumulation of stem-like T cells, leading to improved efficacy of PD-1 immunotherapy; whereas, after exhaustion progressed, mTOR inhibition caused immunosuppression, characterized by decreased TIM3+ cells and increased viral load with minimal changes in stem-like T cells. Mechanistically, a cell-intrinsic mTOR signal was vital for differentiation of stem-like T cells into the TIM3+ state in the early and late phases of chronic infection as well as during PD-1 immunotherapy. Thus, PD-1 blockade worked after cessation of mTOR inhibition, but simultaneous treatment failed to induce functional TIM3+ cells, reducing efficacy of PD-1 immunotherapy. Our data demonstrate that mTOR regulates T cell exhaustion and have important implications for combination cancer therapies with PD-1 blockade.

Authors

Satomi Ando, Charles M. Perkins, Yamato Sajiki, Chase Chastain, Rajesh M. Valanparambil, Andreas Wieland, William H. Hudson, Masao Hashimoto, Suresh S. Ramalingam, Gordon J. Freeman, Rafi Ahmed, Koichi Araki

×

Figure 4

Rapamycin treatment during the beginning of chronic infection improves efficacy of PD-1–targeted therapy.

Options: View larger image (or click on image) Download as PowerPoint
Rapamycin treatment during the beginning of chronic infection improves e...
(A) Experimental design. Mice were infected with LCMV clone 13 in the presence or absence of rapamycin treatment. Rapamycin was i.p. administered every day from day –1 to day 33–36 of infection. Treatment with anti-PDL1 antibody or isotype control antibody was started from the day after rapamycin discontinuation, and these antibodies were i.p. injected every 3 days, for a total of 5 injections. Immune response and viral titer were analyzed at day 14 after PD-1 blockade was started. (B and D) The frequency of DbGP33 tetramer+ CD8+ T cells. Flow cytometry plots were gated on CD8+ T cells. (C and E) The number of DbGP33 tetramer+, DbGP276 tetramer+, and PD-1+CD8+ T cells (n = 14 per each group except for the isotype antibody group treated with rapamycin [n = 15] for spleen, n = 9 per each group except for the isotype antibody group treated with rapamycin [n = 10] for liver). Spleen data are shown in B and C, and liver data are shown in D and E. (F) Viral titers in the spleen and liver. Spleen: isotype with and without rapamycin (n = 10 per each group), anti–PD-L1 with and without rapamycin (n = 15 per each group). Liver: n = 10 per each group. Each symbol represents an individual mouse. Each bar in C and E and each horizontal line in F represent geometric means. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by 1-way ANOVA. Data were pooled from 2 or 3 independent experiments.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts